Skip to main content
SpringerLink
Log in
Book cover

Psychiatric Drugs in Children and Adolescents pp 337–350Cite as

Aggressive and Autoaggressive Behavior, Impulse Control Disorder, and Conduct Disorder

  • Chapter
  • First Online:

Abstract

Aggressive behavior can occur alone or as an accompanying symptom or consequence of various psychiatric disorders as classified in the International Classification of Diseases, 10th revision (ICD-10) and the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Aggression can be directed against oneself (self-injury, suicidal thoughts, and acts) or against others. Aggressive behavior can be the symptom of the different kinds of disruptive behavior (e.g., oppositional defiant disorder, conduct disorder, antisocial personality disorder), of emotional dysregulation (e.g., borderline personality disorder), of disturbance of impulse control (attention deficit/hyperactivity disorder, ADHD), of cognitive deficiency (e.g., co-occurring with intellectual disabilities, pervasive developmental disorders, with psychosis or bipolar disorder), and of trauma or stress (e.g., post-traumatic stress disorder, adjustment disorders), and the aggressive behavior may be drug-induced. Thus each kind of behavioral and psychopharmacological treatment of the symptoms of aggression depends on the associated individual conditions of the aggression. Various subtypes will benefit differently from pharmacotherapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literature

  • Aman MG, Lindsay RL (2002) Psychotropic medicines and aggressive behaviour. I Child Adolesc Psychopharmacol 7:1–6

    Article  Google Scholar 

  • Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, and the Risperidone Disruptive Behavior Study Group (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337–1346

    Article  PubMed  Google Scholar 

  • Aman MG, Binder C, Turgay A (2004) Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243–254

    Article  PubMed  Google Scholar 

  • American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn (DSM-5TM). American Psychiatric Publishing, Washington/London

    Google Scholar 

  • Armenteros JL, Lewis JE (2002) Citalopram treatment for impulsive aggression in children and adolescents: an open pilot-study. J Am Acad Child Adolesc Psychiatry 41:522–552

    Article  PubMed  Google Scholar 

  • Armenteros JL, Lewis JE, Davalos M (2007) Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 46:558–565

    Article  PubMed  Google Scholar 

  • Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM (2006) The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol 16:665–670

    Article  PubMed  Google Scholar 

  • Beherec L, Lambrey S, Quilici G, Rosier A, Falissard B, Guillin O (2011) Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J Clin Psychopharmacol 31:341–344

    Article  CAS  PubMed  Google Scholar 

  • Biederman Baldessarini RJ, Wright V, Knee D (1989) A double-blind placebo controlled-study of desipramine in the treatment of ADD. 1. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777–784

    Article  Google Scholar 

  • Blader JC, Schooler NR, Jensen PS, Pliska SR, Kafantaris V (2009) Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry 166:1392–1401

    Article  PubMed Central  PubMed  Google Scholar 

  • Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V (2010) Stimulant-responsive and stimulant-refractory aggressive behaviors among children with ADHD. Pediatrics 126:E796–E806

    Article  PubMed Central  PubMed  Google Scholar 

  • Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, Kuiper M (1996) Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. J Child Psychol Psychiatry 37:587–595

    Article  CAS  PubMed  Google Scholar 

  • Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CTM (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239–248

    Article  CAS  PubMed  Google Scholar 

  • Bukstein OG, Kolko DJ (1998) Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. J Clin Child Adolesc 27:340–351

    Article  CAS  Google Scholar 

  • Campbell M, Small AM, Green WH, Jennings MA, Perry R, Bennett WG, Anderson L (1984) A comparison of haloperidol and lithium in hospitalized aggressive conduct disordered children. Arch Gen Psychiatry 41:650–656

    Article  CAS  PubMed  Google Scholar 

  • Campbell M, Adams PB, Small AM, Kafantaris V, Shell J, Perry R, Overall JE (1995) Lithium in hospitalized aggressive-children with conduct disorder – a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 34:445–453

    Article  CAS  PubMed  Google Scholar 

  • Carlson GA, Rapport MD, Pataki CS, Kelly KL (1992) Lithium in hospitalized children at 4 and 8 weeks. Mood, behavior and cognitive effects. J Child Psychol Psychiatry 33:411–425

    Article  CAS  PubMed  Google Scholar 

  • Chalasani L, Kant R, Chengappa R (2001) Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Can J Psychiatry 46:965–968

    CAS  PubMed  Google Scholar 

  • Comai S, Tau M, Gobbi G (2012a) The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. J Clin Psychopharmacol 32:83–94

    Article  PubMed  Google Scholar 

  • Comai S, Tau M, Pavlovic Z, Gobbi G (2012b) The psychopharmacology of aggressive behavior: a translational approach. Part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol 32:237–260

    Article  CAS  PubMed  Google Scholar 

  • Connor DF, Ozbayrak KR, Ma YS, Fletcher KE (1997) A pilot study of nadolol for overt aggression in developmentally delayed individuals. J Am Acad Child Adolesc Psychiatry 36:826–834

    Article  CAS  PubMed  Google Scholar 

  • Connor DF, Fletcher KE, Swanson JM (1999) A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 38:1551–1559

    Article  CAS  PubMed  Google Scholar 

  • Connor DF, Barkley RA, Davis HT (2000) A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr 39:15–25

    Article  CAS  Google Scholar 

  • Connor DF, McLaughlin TJ, Jeffers-Terry M (2008) Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol 18:140–156

    Article  PubMed  Google Scholar 

  • Connor DF, Findling RL, Kollins SH, Sallee F, Lopez FA, Lyne A, Tremlay G (2010) Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms. A randomized, double-blind, placebo-controlled trial. CNS Drugs 24:755–768

    CAS  PubMed  Google Scholar 

  • Correll CU, Kratochvil CJ, March JS (2011) Development in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 72:655–670

    Article  PubMed  Google Scholar 

  • Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S (2005) Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64–72

    Article  PubMed  Google Scholar 

  • Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M (1996) Carbamacepine in aggressive children with conduct disorder: a double-bind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 38(35):480–490

    Article  Google Scholar 

  • Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM (2011) Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol 21:97–110

    Article  CAS  PubMed  Google Scholar 

  • Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel W, Susser E, Klein DF (2000) Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 157:818–820

    Article  CAS  PubMed  Google Scholar 

  • Findling RL, Reed MD, O’Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK (2007) A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol 17:1–9

    Article  PubMed  Google Scholar 

  • Findling RL, Kaufman R, Sallee FR, Salazar DE, Sahasrabudhe V, Kollia G, Kornhauser DM, Vachharajani NN, Assuncao-Talbott S, Mallikaarjun S, Iwamoto T, McQuade RD, Boulton DW, Blumer J (2009) An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 19:431–439

    Article  PubMed  Google Scholar 

  • Frankenhauser MP, Karumanchi V, German ML, Yates A, Karumanchi SD (1992) A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53:77–82

    Google Scholar 

  • Gerardin P, Cohen D, Mazet P, Flament MF (2002) Drug treatment of conduct disorder in young people. Eur Neuropsychopharmacol 12:361–370

    Article  CAS  PubMed  Google Scholar 

  • Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ (2012) Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 69:580–587

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Goedhard LE, Stolker JJ, Herrdink ER, Nijman HL, Olivier B, Egberts CG (2006) Pharmacotherapy of aggressive behavior in general adult psychiatry: a systematic review. J Clin Psychiatry 67:1013–1024

    Article  CAS  PubMed  Google Scholar 

  • Hazell P, Stuart J (2003) A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 42:886–894

    Article  PubMed  Google Scholar 

  • Hechtman L, Greenfiled B (2003) Long-term use of stimulants in children with attention deficit hyperactivity disorder. Pediatr Drugs 5:787–794

    Article  Google Scholar 

  • Hollander E (1999) Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline disorder. J Clin Psychiatry 60(Suppl 15):38–44

    PubMed  Google Scholar 

  • Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S (2006) A double-blind placebo-controlled study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16:541–548

    Article  PubMed  Google Scholar 

  • Ipser J, Stein DJ (2007) Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents. Psychopharmacology (Berl) 191:127–140

    Article  CAS  Google Scholar 

  • Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL (1992) Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322–327

    Article  CAS  PubMed  Google Scholar 

  • Jensen PS, Youngstrom E, Steiner H, Findling RL, Meyer RE, Malone RP, Carlson GA, Coccaro EF, Aman MG, Blair J, Dougherty D, Ferris C, Flynn L, Green E, Hoagwood K, Hutchinson J, Laughren T, Leve LD, Novins DK, Vitiello B (2007) Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry 46:309–322

    Article  PubMed  Google Scholar 

  • Kaizar EE, Greenhouse JB, Seltman H, Kelleher K (2006) Do antidepressants cause suicidality in children? A Bayesian meta-analysis. Clin Trials 3:73–90

    Article  PubMed  Google Scholar 

  • Khan SS, Mican LM (2006) A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J Child Adolesc Psychopharmacol 16:671–677

    Article  PubMed  Google Scholar 

  • Kowatch RA, Bucci JB (1998) Mood stabilizers and anticonvulsants. Pediatr Clin North Am 45:1173–1186

    Article  CAS  PubMed  Google Scholar 

  • Kranzler H, Roofeh D, Gerbino-Rosen G, Dombrowski C, McMeniman M, DeThomas C, Frederickson A, Nusser L, Bienstock MD, Fisch GS, Kumra S (2005) Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 44:55–63

    Article  PubMed  Google Scholar 

  • Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW (2007) Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid attention-deficit/hyperactivity disorder, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol 17:334–347

    Article  PubMed  Google Scholar 

  • Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch CV, Bauer T, Xu W, Wang W, Carlson J, Tohen M (2009) Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:60–70

    Article  PubMed  Google Scholar 

  • LeBlanc JC, Binder CE, Armenteros JL, Aman MG, Wang JS, Hew H, Kusumakar V (2005) Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. Int Clin Psychopharmacol 20:275–283

    Article  PubMed  Google Scholar 

  • Lindenmayer JP, Kotsaftis A (2000) Use of sodium valproate in violent and aggressive behaviours: a critical review. J Clin Psychiatry 61:123–128

    Article  CAS  PubMed  Google Scholar 

  • Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M (2000) A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. JAMA 57:649–654

    CAS  Google Scholar 

  • Malone RP, Delaney MA, Hyman SB, Cater JR (2007) Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 17:779–790

    Article  PubMed  Google Scholar 

  • Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Corey-Lisle PK, Aman MG (2011) Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 21:229–236

    Article  CAS  PubMed  Google Scholar 

  • McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, for Research Units on Pediatric Psychopharmacology Autism Network (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 357:314–321

    Article  Google Scholar 

  • McDougle CJ, Kem DL, Posey DJ (2002) Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921–927

    Article  PubMed  Google Scholar 

  • Michelson D, Buitelaar JK, Dankaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang SY, Biederman J (2004) Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43:896–904

    Article  PubMed  Google Scholar 

  • Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A (2005) Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 15:259–269

    Article  PubMed  Google Scholar 

  • Nagaraj R, Singhi P, Malhi P (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 21:450–455

    PubMed  Google Scholar 

  • Nevels RM, Dehon EE, Alexander K, Gontkovsky ST (2010) Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 18:184–201

    Article  PubMed  Google Scholar 

  • Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D (2005) Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 44:240–248

    Article  PubMed  Google Scholar 

  • Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533–1540

    Article  PubMed  Google Scholar 

  • Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F (2007) Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 37:367–373

    Article  PubMed  Google Scholar 

  • Pappadopulos E, Mac Intyre JC II, Crismon L, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS (2003) Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 42:145–161

    Article  PubMed  Google Scholar 

  • Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS (2006) Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry 15:27–39

    PubMed Central  PubMed  Google Scholar 

  • Parikh MS, Kolevzon A, Hollander E (2008) Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 18:157–178

    Article  PubMed  Google Scholar 

  • Polzer J, Bangs ME, Zhang SY, Dellva MA, Tauscher-Wisniewski S, Acharya N, Watson SB, Allen AJ, Wilens T (2007) Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. Biol Psychiatry 61:713–719

    Google Scholar 

  • Quintero J, Lopez-Munoz F, Cecilio LM, Garcia-Campos N (2010) Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study. Attent Defic Hyperact Disord 2:107–113

    Article  Google Scholar 

  • Ratner S, Laor N, Bronstein Y, Weizman A, Toren P (2005) Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 44:428–433

    Article  PubMed  Google Scholar 

  • Reyes M, Croonenberghs J, Augustyns I, Eerdekens M (2006) Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16:260–272

    Article  PubMed  Google Scholar 

  • Saxena K, Howe M, Simenonova D, Steiner H, Chang K (2006) Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder. J Child Adolesc Psychopharmacol 16:252–259

    Article  PubMed  Google Scholar 

  • Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J, Lee JC, Wang PS (2010) Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics 125:876–888

    Article  PubMed Central  PubMed  Google Scholar 

  • Siever LJ (2008) Neurobiology of aggression and violence. Am J Psychiatry 165:429–442

    Article  PubMed  Google Scholar 

  • Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, for the Risperidone Conduct Study Group (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026–1036

    Article  PubMed  Google Scholar 

  • Steiner H, Petersen ML, Saxena K, Ford S, Matthews Z (2003) Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 64:1183–1191

    Article  CAS  PubMed  Google Scholar 

  • Steiner H, Silverman M, Karnik NS, Huemer J, Plattner B, Clark CE, Blair JR, Haapanen R (2011) Psychopathology, trauma and delinquency: subtypes of aggression and their relevance for understanding youth offenders. Child Adolesc Psychiatry Ment Health 5:21. doi:10.1186/1753-2000-5-21

    Article  PubMed Central  PubMed  Google Scholar 

  • Stephens RJ, Bassel C, Sandor P (2004) Olanzapine in the treatment of aggression and tics in children with Tourette’s Syndrome – a pilot study. J Child Adolesc Psychopharmacol 14:255–266

    Article  PubMed  Google Scholar 

  • Tehrani-Doost M, Moallemi S, Shahrivar Z (2008) An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 18:179–184

    Article  PubMed  Google Scholar 

  • The MTA Cooperative Group (1999) A 14 month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073–1086

    Article  Google Scholar 

  • Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J (2007) Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164:1547–1556

    Article  PubMed  Google Scholar 

  • Toren P, Ratner S, Weizman A, Lask M, Ben-Amitay G, Laor N (2007) Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: a long-term follow-up open study. J Child Adolesc Psychopharmacol 17:803–811

    Article  PubMed  Google Scholar 

  • Troost PW, Lahius BE, Steenhuis MP, Ketelaars CEJ, Buitelaar JK, Van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137–1144

    Article  PubMed  Google Scholar 

  • Tsiouris JA (2010) Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment. J Intellect Disabil Res 54:1–16

    Article  CAS  PubMed  Google Scholar 

  • Turgay A, Binder C, Snyder R, Fisman S (2002) Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with subaverage IQs. Pediatrics 110:e34

    Article  PubMed  Google Scholar 

  • Valicenti-McDermott MR, Demb H (2006) Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 16:549–560

    Article  PubMed  Google Scholar 

  • Volavka J, Citrome L (1999) Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res 35(Suppl):S23–S33

    Article  PubMed  Google Scholar 

  • Walsh MT, Dinan TG (2001) Review article: Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand 104:84–91

    Article  CAS  PubMed  Google Scholar 

  • Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:647–655

    Article  PubMed  Google Scholar 

  • World Health Organisation (1996) Multiaxial classification of child and adolescent psychiatric disorders. The ICD – 10 Classification of Mental and Behavioral Disorders in Children and Adolescents. Cambridge University Press, Cambridge

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Steinhövelstr. 5, 89075, Ulm, Germany

    Claudia Mehler-Wex MD

  2. HEMERA-Klinik, Schönbornstr. 16, 97688, Bad Kissingen, Germany

    Claudia Mehler-Wex MD

  3. Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Füchsleinstr. 15, 97080, Würzburg, Germany

    Marcel Romanos MD & Andreas Warnke MD

Authors
  1. Claudia Mehler-Wex MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcel Romanos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas Warnke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia Mehler-Wex MD .

Editor information

Editors and Affiliations

  1. Kinder- und Jugendpsychiatrie, Universitätsklinikum Würzburg Klinik und Poliklinik, Würzburg, Germany

    Manfred Gerlach

  2. Jugendpsychiatrie und Psychotherapie, Universitätsklinikum Würzburg Klinik und Poliklinik für Kinder- und, Würzburg, Germany

    Andreas Warnke

  3. Child and Adolescent Psychiatry New York Presbyterian Hospital, New York, New York, USA

    Laurence Greenhill

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Wien

About this chapter

Cite this chapter

Mehler-Wex, C., Romanos, M., Warnke, A. (2014). Aggressive and Autoaggressive Behavior, Impulse Control Disorder, and Conduct Disorder. In: Gerlach, M., Warnke, A., Greenhill, L. (eds) Psychiatric Drugs in Children and Adolescents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1501-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1501-5_9

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1500-8

  • Online ISBN: 978-3-7091-1501-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation